AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company ...
AbbVie Inc. Q4 2025 shows SKYRIZI/RINVOQ strength but diversification risks and M&A reliance. Click here to read this earnings analysis of ABBV stock.
Q4 2025 earnings call highlights: record sales, Skyrizi/Rinvoq momentum, 2026 guidance ($67B) and risks—read key takeaways.
The legislation will impose new restrictions on pharmacy benefit managers, giant companies like CVS Caremark, Optum Rx and ...
AbbVie Inc. forecast 2026 profits above Wall Street’s expectations.
The choice between the two might come down to each investor's goals and risk tolerance.
By diving deeper into the dynamics of high-cost claims, employers can uncover valuable insights that pave the way for smart, ...
Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into supply ...
Kenvue Inc. (NYSE: KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February ...
AbbVie's immunology portfolio was led by arthritis and Crohn's disease drugs Skyrizi and Rinvoq, for which revenue rose 32.5% and 29.5% respectively. That offset a 26% decline for immune-disease ...
Injectable dermal products have become some of the most sought-after cosmetic treatments. But behind every injection lies a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results